Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascentage Pharma Group International ( (HK:6855) ) just unveiled an update.
Ascentage Pharma Group International has announced the current composition of its board of directors, led by Executive Director and Chairman Dr. Yang Dajun and supported by a mix of non-executive and independent non-executive directors with scientific, medical, and industry expertise. The company has also detailed the membership and leadership of its key governance committees—Audit, Remuneration, Nomination, and Research and Development—clarifying the roles of each director as chair or member, a move that underscores its emphasis on formalized oversight, corporate governance, and R&D-focused decision-making as it advances its business and regulatory obligations.
The most recent analyst rating on (HK:6855) stock is a Hold with a HK$63.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on innovative drug research and development, with operations based in Suzhou, China, and a listing on the Hong Kong Stock Exchange under stock code 6855. The company’s activities center on advancing pharmaceutical R&D, supported by a governance structure that includes executive, non-executive, and independent non-executive directors overseeing its strategic and operational direction.
Average Trading Volume: 1,934,841
Technical Sentiment Signal: Hold
Current Market Cap: HK$19.85B
Find detailed analytics on 6855 stock on TipRanks’ Stock Analysis page.